Wilson Lucy E, Gallant Joel E
Division of Infectious Diseases, Johns Hopkins School of Medicine, 1830 E. Monument Street, Baltimore, MD 21287, USA.
Clin Infect Dis. 2009 Jan 15;48(2):214-21. doi: 10.1086/595701.
The recent availability of new antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection has increased treatment options and has improved the durability, tolerability, and long-term efficacy of antiretroviral therapy, even among patients with extensive treatment experience and high levels of drug resistance. This expansion of therapeutic options has led to a revision of current treatment guidelines, which now state that the goal of antiretroviral therapy in all patients is suppression of the plasma HIV RNA level to <50 copies/mL. Successful management of infection for treatment-experienced patients with the new agents requires an understanding of their pharmacology and resistance patterns and the appropriate use of laboratory testing to optimize regimen selection. This review discusses the use of recently approved antiretroviral agents in the management of HIV infection in treatment-experienced patients.
近期可用于治疗人类免疫缺陷病毒（HIV）感染的新型抗逆转录病毒药物增加了治疗选择，并提高了抗逆转录病毒疗法的持久性、耐受性和长期疗效，即使在具有丰富治疗经验和高耐药水平的患者中也是如此。治疗选择的这种扩展导致了当前治疗指南的修订，现在指南指出，所有患者抗逆转录病毒治疗的目标是将血浆HIV RNA水平抑制到<50拷贝/毫升。对于有治疗经验的患者，使用新型药物成功管理感染需要了解其药理学和耐药模式，并适当使用实验室检测以优化治疗方案的选择。本综述讨论了最近批准的抗逆转录病毒药物在有治疗经验的HIV感染患者管理中的应用。
